| Bioactivity | MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and HDAC6, respectively[1]. MPT0E028 reduces the viability of B-cell lymphomas by inducing apoptosis and possesses potent direct Akt targeting ability and reduces Akt phosphorylation in B-cell lymphoma. MPT0E028 has good anticancer activity[2]. |
| Name | MPT0E028 |
| CAS | 1338320-94-7 |
| Formula | C17H16N2O4S |
| Molar Mass | 344.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | 4°C, sealed storage, away from moisture and light *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture and light) |
MPT0E028
CAS: 1338320-94-7 F: C17H16N2O4S W: 344.38
MPT0E028 is an orally active and selective HDAC inhibitor with IC50s of 53.0 nM, 106.2 nM, 29.5 nM for HDAC1, HDAC2 and
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.